BTL Vanquish Receives FDA Approval

The U.S. Food and Drug Administration (FDA) has approved the BTL Vanquish for circumferential reduction of the abdomenal area. The platform features a panel array that emits selective RF energy with the largest spot size in the industry to treat the entire core in one application (without touching patients’ skin). It creates a high-frequency energy field that targets the thermal effects into the fat layer while protecting surrounding skin tissue. “FDA clearance of BTL Vanquish marks a defining moment in our journey to provide physicians and their patients an elegant treatment option to target fat cells and bring about a reduction in the waist circumference,” says Andrea Morrison, BTL director of clinical development. “BTL is proud to offer patients a comfortable, affordable and noninvasive body shaping experience. This regulatory milestone underscores BTL’s commitment to deliver meaningful solutions to aesthetic patient care.”

Suggested Articles

INhance Post-Injection Serum with TriHex Technology is designed to alleviate bruising caused by cosmetic procedures.

Medical pedicures at Medi Pedi NYC focus specifically on feet and nail health.

Plastic surgery practices have started reopening, allowing clients to receive elective treatments of the face and neck.